In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that there is no standard second line therapy for the treatment of hepatocellular carcinoma (HCC).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER
© 2017 Imedex, LLC.